Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Sellas Life Sciences Group, Inc.

NASDAQ: SLS · Life Sciences · 3 alerts · CIK 1390478

Share price
$7.47Close, Nov 16
Market cap
$1.52B
Shares outstanding
203.86MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Sellas Life Sciences Group, Inc. filings on SEC EDGAR ↗

4:08 PM ET 8-K
Financial Results

Sellas Life Sciences Group Financial Results

SELLAS Life Sciences reported its third quarter 2026 financial results, highlighting a cash position of $134.7 million. The company expects to report topline primary endpoint results from its Phase 3 REGAL trial of GPS in AML later this month and preliminary topline data for SLS009 in first-line AML in Q4 2026.

Term
Q3 2026

“We continue to execute across both of our clinical programs as we approach several important milestones. In our ongoing Phase 3 REGAL trial of GPS, we are focused on completing the final analysis following the announcement of 80th event, and we expect to announce topline primary endpoint results this month. If successful, we believe GPS could be a transformative new immunotherapy for AML patients in second complete remission.”

Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer

“In parallel, enrollment and dosing continue in our Phase 2 trial of tambiciclib (SLS009) in newly diagnosed AML, with preliminary topline data expected in the fourth quarter. As announced earlier this month, we look forward to presenting our Phase 2 data in relapsed/refractory AML at the upcoming ASH in December. We were also encouraged by the preclinical data presented at AACR in pancreatic cancer models, including in resistance to a RAS inhibitor, and we are continuing our preparations for clinical development in that indication. With $134.7 million in cash and cash equivalents as of September 30, we are well positioned to further advance these programs.”

Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer
4:01 PM ET 10-Q
Financial Results

Sellas Life Sciences Group Q3 2026 Results: Net Loss of $10.1M, Loss Widens

SELLAS Life Sciences Group reported a net loss of $10.1 million for the third quarter of 2026, compared to $6.8 million in the prior year period, driven by increased research and development expenses. The company strengthened its balance sheet significantly, ending the period with $134.7 million in cash and cash equivalents following substantial warrant exercises during the nine months ended September 30, 2026.

Key figure
Net loss $10.1M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.